Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | FPR2 | P25090 | 5/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457306 | 0.86 | FPR2 (0.35) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL1641772 | 0.83 | L3MBTL1 (0.43) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL4636620 | 0.82 | MCL1 (0.48) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL1626536 | 0.82 | L3MBTL1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL2650212 | 0.82 | L3MBTL1 (0.46) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL6205744 | 0.82 | L3MBTL1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL3941116 | 0.82 | L3MBTL1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL347771 | 0.81 | TSHR (0.44) | FPR2PROKR1GAANMT1ALDH1A1 | |
| SCHEMBL13677614 | 0.80 | HTR6 (0.44) | L3MBTL1FPR2PROKR1MCL1ACLY | |
| SCHEMBL9202305 | 0.80 | NMT1 (0.42) | L3MBTL1FPR2PROKR1MCL1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-09 | — | — | US | disclosed |
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-5852007-A | Cysteine and serine protease inhibitors containing D-amino acid at the P2 position, methods of making same, and methods of using same | CEPHALON, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1037568-C | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1998-03-04 | — | — | CN | disclosed |
| WO-1997036580-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0511826-B1 | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5500405-A | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0087780-B2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL IND LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| US-5272128-A | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0511826-A2 | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
| US-4954164-A | Pyrazolesulfonylurea derivatives, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0087780-A2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | L3MBTL1 3468/4885FPR2 3638/4885PROKR1 1/4885 |
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | L3MBTL1 3468/4885FPR2 3638/4885PROKR1 1/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | L3MBTL1 1949/4885FPR2 3822/4885PROKR1 1073/4885 |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | L3MBTL1 3383/4885FPR2 3719/4885PROKR1 1/4885 |
| US-11555012-B2 | ACLY inhibitors and uses thereof | ACLY, ATP5ME, ATP5MG | L3MBTL1 2716/4885FPR2 4795/4885PROKR1 4267/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | L3MBTL1 1353/4885FPR2 716/4885PROKR1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.